AWARDDEFINITIVE CONTRACTSmall business
Definitive contract 75N91023C00015NOMOCAN PHARMACEUTICALS LLC
Overview
Award facts
- Net obligations
- $354.96K
- $354,959of $354.96K potential value
- Outlays (paid to date)
- $354.96K
- $354.96K paid of $354.96K obligated$354,959
- Period of performance
- Feb 27, 2023 to Nov 26, 2024
- Ended
- Modifications
- 2
- Latest action Mar 21, 2024
- Contract type
- Definitive contract
- PIID 75N91023C00015
Contract value is the most the government could spend; obligations are what it has legally committed; outlays are what it has actually paid.
Description of requirement
PC HAS ONE OF THE LOWEST 5-YEAR SURVIVAL RATES AMONG ALL CANCER TYPES, REMAINING BELOW 10% FOR THE PAST 40 YEARS, INDICATING A NEED FOR EFFECTIVE PC THERAPIES. STUDIES HAVE SHOWN THAT NMC-521 BINDS SELECTIVELY TO SEVERAL PC CELL LINES WITH MARKED ANT
Dates and value
- Award date
- Signed on Feb 27, 2023
- Potential end of performance
- Nov 25, 2024
- Current value
- $354,959Base and exercised options
- Potential value (if all options are exercised)
- $354,959
Obligations by fiscal year of action
- FY2023: $354,959
Total across 1 fiscal year: $354,959
Source: Federal Procurement Data System contract actions as published by SAM.gov and USAspending.gov; latest action recorded Mar 21, 2024. View on USAspending · Recipient on SAM.gov
Recipient
LocationNEW YORK, NY
UEIH9T8M7ZBYAR8
CAGE code7ER28
Business sizeSmall businessSize at award, per the contracting officer
Organization typeCorporate not tax exempt
Parent companyNOMOCAN PHARMACEUTICALS LLC
Business types and certifications
For-profit organizationLimited liability companyCorporation (not tax-exempt)
As represented in SAM.gov at the time of the action.
Subcontracting network
The prime, the subcontractors on this award, and their own subcontractors.
Agency and place
Awarding and funding
- Awarded by
- Funded by
- Department of Health and Human Services
- National Institutes Of Health
- NIH NCI
- Funded from
- National cancer institute (0849)Program activities075-0849Federal accounts (agency financial reports)
Place of performance
- Place of performance
- New York, New York 10065-6275
- Congressional district (place of performance)
- NY-12As reported at the time of the action
Classification and competition
Classification
- Product or service (PSC)
- AN12HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH (research and development)
Competition
- Extent competed
- Full and open competition after exclusion of sourcesD
- Solicitation procedures
- Negotiated proposal/quoteNP
- Set-aside
- Small business set aside - totalSBA
- Contract pricing
- Firm fixed priceJ
- Offers received
- 17
Solicitation and notices
- Solicitation ID
- 75N91022R00006
- Solicitation date
- Aug 22, 2022
- Notices
- Solicitation posted Mar 17, 2022
- Presolicitation posted Feb 10, 2022
Contract details
- Subcontracting plan
- Plan not requiredB
- Cost Accounting Standards clause
- Not applicable exempt from CASX
- Certified cost or pricing data
- No
- Commercial procedures
- Commercial products/services procedures not usedD
- Government-furnished property
- Transaction does not use GFE/GFPN
- Bundled requirement
- Not bundledH
- Consolidated requirement
- Not consolidatedD
- Undefinitized action (terms not final)
- No
- Multi-year contract
- No
- Performance-based service acquisition
- No - service where PBA is not used.N
Linked notices
Notice | Notice ID | Type | Link | Posted |
|---|---|---|---|---|
Transaction history
Modification history
- Base award
- Feb 27, 2023Base obligation at award: $299,959
- Latest action
- Mar 21, 2024 — Other administrative actionModification P00002; administrative: no change in scope or value
- Latest substantive action
- Jul 13, 2023 — Option exercisedModification P00001; obligation change +$55,000
- Actions by type
- Base award1
- Option exercised1
- Other administrative action1
Similar awards
PIID | Match | Awardee |
|---|---|---|
All contract data
All contract data
Every other field reported for this award, as of its latest reported action
Competition
- Evaluation preference
- No preference used
- Local area set-aside
- No
- Synopsized publicly (SAM.gov / FedBizOpps)
- Yes
- Simplified procedures for commercial items
- No
Pricing and financing
- Paid by purchase card
- No
Socio-economic and policy
- Inherently governmental functions
- Other functionsOT
- Recovered materials and sustainability
- No clauses included and no sustainability includedC
- EPA-designated product
- Not requiredE
- Clinger-Cohen Act planning (IT)
- No
- Research program (SBIR/STTR)
- Small business innovation research program phase i actionSR1
Place and origin
- Domestic or foreign entity
- U.S. owned businessA
- Country of product or service origin
- United statesUSA
- Place of manufacture
- Not a manufactured end productC
Structure
- Award or IDV
- Award
- Award type
- Definitive contractD
- Awarding agency code
- 7500
- Awarding sub-tier code
- 7529
- Contracting office code
- 75N910
- Transactions recorded under this award key
- 3
Funding
- Funding agency code
- 7500
- Funding sub-tier code
- 7529
- Funding office code
- 75N910
- Treasury accounts
- 075-2023/2023-0849-000
- Object classes
- 25.2: Other services from non-Federal sources
- Disaster or emergency funding (DEFC)
- Q: Not Designated Nonemergency/Emergency/Disaster/Wildfire Suppression